Ertugliflozin (L-pyroglutamic acid) / sitagliptin (phosphate monohydrate) Medicine 09 January 2018 Extended indication Diabetes mellitus type 2 Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Ertugliflozin (L-pyroglutamic acid) / sitagliptin (phosphate monohydrate) Domain Metabolism and Endocrinology Reason of inclusion Main indication Diabetes Extended indication Diabetes mellitus type 2 Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer MSD Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Samenwerking tussen MSD en Pfizer, MSD is de registratiehouder. Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date May 2017 Expected Registration April 2018 Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Voor ertugliflozin/sitagliptin (een dpp-iv remmer) isgeen meerwaarde te verwachten tov de momenteel al op de markt zijnde combinatiepreparaten van een SGLT2 remmer met een dpp-iv remmer. Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks